The PROTECT for Rare Act expands Medicare and Medicaid coverage for rare disease treatments and establishes an expedited appeals process for private insurance coverage denials.
Thom Tillis
Senator
NC
The PROTECT for Rare Act aims to improve patient access to life-saving treatments by expanding Medicare and Medicaid coverage for drugs used to manage rare diseases. Additionally, the bill establishes an expedited appeals process for private insurance denials, ensuring that patients with rare conditions can more easily access medically supported therapies.
New PROTECT for Rare Act Mandates Medicare and Private Insurance Coverage for Rare Disease Drugs Starting in 2027
If you or someone you love is one of the 25 to 30 million Americans living with a rare disease, you know the 'off-label' struggle. Often, a drug exists that could help, but because the disease affects fewer than 200,000 people, the FDA hasn't officially labeled the drug for that specific use. This bill, the PROTECT for Rare Act, aims to fix the insurance wall patients hit by expanding the definition of a 'medically accepted indication.' Starting January 1, 2027, Medicare Parts B and D, along with Medicaid, would be required to cover drugs for rare conditions as long as the treatment is backed by peer-reviewed medical literature or clinical guidelines and isn't specifically flagged as 'not indicated' or dangerous by the FDA.
Breaking the Coverage Barrier
Under current rules, getting insurance to pay for a rare disease treatment can feel like a full-time job of filing paperwork and crossing fingers. This legislation changes the game by requiring Medicaid to recognize a drug's use if it’s supported by medical societies or experts in that specific field (Section 1927(k)(6)). For a parent managing a child’s ultra-rare metabolic disorder, this means the difference between a denied claim and a covered prescription, provided the treatment is supported by the latest clinical research. It essentially forces insurance companies to keep pace with medical science rather than hiding behind outdated labels.
Fast-Tracking the 'No'
We’ve all been there: waiting weeks for an insurance company to tell you 'no' while your health hangs in the balance. The bill introduces a heavy-hitting requirement for private group and individual health plans: an expedited appeals process. If your insurance denies a rare disease drug that meets the bill's criteria—meaning it's FDA-approved for something and backed by medical literature for your condition—you, your doctor, or a designee can trigger a high-speed review. This provision, added to the Public Health Service Act and ERISA, ensures that 'busy work' at an insurance office doesn't delay life-altering care for those with limited options.
The Fine Print and Future Hurdles
While this is a massive win for patient access, the rollout isn't happening tomorrow. The January 1, 2027, start date gives insurers and government programs a long lead time to update their systems. The real-world challenge will likely lie in the definition of 'peer-reviewed literature.' While the bill is clear that the use must be supported by clinical guidelines, we may see friction between doctors who see a drug working in the field and insurance adjusters who want more 'robust' data before cutting a check. However, by shifting the default toward coverage for these small patient populations, the bill removes one of the biggest financial roadblocks in rare disease management.